earli
immun
respons
infect
like
import
factor
determin
clinic
cours
diseas
recent
data
indic
quasispeci
aris
follow
mucos
infect
usual
deriv
singl
transmit
viru
moreov
find
first
effect
immun
respons
drive
select
viru
escap
mutat
provid
insight
earliest
immun
respons
transmit
viru
contribut
control
acut
viraemia
strong
innat
adapt
immun
respons
occur
subsequ
late
elimin
infect
review
discuss
recent
studi
kinet
qualiti
earli
immun
respons
implic
develop
success
prevent
vaccin
natur
review
immunolog
volum
januari
recent
advanc
enabl
identif
patient
within
first
week
infect
provid
research
access
sampl
acut
infect
patient
earlier
higher
number
previous
avail
advanc
understand
natur
transmit
viru
first
immun
respons
period
establish
stabl
viraemia
viral
set
point
occur
month
infect
first
week
follow
transmiss
extrem
dynam
associ
rapid
damag
gener
immun
cell
microenviron
caus
direct
viral
cytopath
bystand
effect
immun
respons
partial
control
viru
review
focu
discuss
earli
host
viral
factor
crucial
determin
outcom
infect
includ
natur
transmit
viru
founder
viru
suppress
initi
infect
genet
influenc
immun
respons
rate
viru
mutat
viral
fit
select
mutant
addit
review
known
natur
innat
adapt
immun
respons
earli
phase
infect
drawn
studi
human
macaqu
infect
simian
immunodefici
viru
siv
respect
final
discuss
knowledg
event
earli
infect
improv
design
prevent
vaccin
transmiss
infect
occur
sexual
exposur
genit
tract
rectal
mucosa
although
possibl
studi
first
event
follow
transmiss
human
vivo
gain
understand
studi
mucos
tissu
explant
infect
vitro
understand
first
stage
infect
vivo
obtain
studi
macaqu
inocul
intrarect
intravagin
siv
still
uncertain
whether
transmit
free
cellbound
viru
siv
transmit
either
form
addit
mechan
cross
genit
mucos
epithelium
unclear
diffus
across
vagin
mucosa
slow
cervicovagin
mucu
possibl
viru
reach
mucos
epithelium
cross
barrier
transcytosi
make
direct
contact
dendrit
intraepitheli
dendrit
cell
dc
preliminari
unpublish
find
suggest
virion
may
also
move
intercellular
space
epithelium
make
initi
cell
contact
underli
mucos
langerhan
cell
cell
hope
mccoomb
person
commun
given
multipl
sexual
exposur
usual
need
infect
occur
cross
epitheli
cell
barrier
viru
probabl
rare
event
although
common
genit
mucosa
damag
physic
trauma
coexist
genit
infect
time
plasma
viraemia
settl
stabl
level
within
approxim
month
onset
hiv
infect
viral
set
point
partial
predict
quickli
hiv
infect
progress
risk
hiv
transmiss
transmit
viru
viru
give
rise
viru
quasispeci
infect
individu
abil
viru
replic
given
environ
definit
vitro
studi
drugresist
viru
greater
abil
replic
wildtyp
viru
measur
presenc
drug
similarli
cell
escap
mutant
replic
better
wildtyp
viru
cocultur
specif
cell
cellresist
drugresist
viru
may
replic
less
well
wild
type
select
forc
withdrawn
type
dendrit
cell
resid
epitheli
layer
skin
mucosa
method
dna
sequenc
use
highfidel
polymeras
minim
pcr
amplif
therebi
exclud
sequenc
error
recombin
event
may
introduc
amplif
hiv
subdivid
base
degre
sequenc
diverg
three
major
group
n
group
subdivid
subtyp
clade
clade
c
predomin
subtyp
worldwid
preval
subsaharan
africa
india
clade
b
studi
subtyp
preval
north
america
eastern
europ
distribut
nonident
close
relat
viral
genom
entir
distribut
form
organ
cooper
structur
act
like
quasi
singl
unit
speci
famili
host
antivir
protein
introduc
multipl
mutat
includ
stop
codon
retrovirus
deamin
cytosin
residu
nascent
retrovir
cdna
eclips
phase
follow
transmiss
viru
period
day
known
eclips
phase
viral
rna
becom
detect
plasma
fig
singlegenom
amplif
sequenc
first
detect
viru
shown
mucos
transmit
clade
b
c
infect
initi
singl
viru
infecti
molecular
clone
deriv
primari
founder
virus
could
infect
cell
greater
effici
could
infect
monocyt
macrophag
differ
viru
quasispeci
aris
later
infect
infect
lymphoid
myeloid
cell
type
equal
effici
studi
rhesu
macaqu
inocul
intrarect
complex
siv
quasispeci
also
show
product
infect
aris
singl
infect
viru
support
use
siv
infect
rhesu
macaqu
model
transmiss
vaccin
studi
studi
macaqu
infect
experiment
first
cell
infect
vagin
mucosa
found
foci
resid
memori
cell
express
viru
receptor
ccchemokin
receptor
consist
cell
tropism
clone
founder
viru
homogen
founder
viru
indic
establish
infect
probabl
aris
singl
focu
infect
mucos
cell
viru
replic
focu
might
fact
support
earli
innat
immun
respons
lead
recruit
addit
suscept
cell
site
failur
infect
foci
becom
establish
may
explain
high
error
rate
revers
transcript
occur
replic
effect
host
antivir
apolipoprotein
b
mrnaedit
enzym
catalyt
polypeptidelik
apobec
cytidin
deaminas
caus
mani
virus
produc
infect
cell
defect
end
eclips
phase
viru
andor
virusinfect
cell
reach
drain
lymph
node
meet
activ
cell
target
infect
process
augment
dc
bind
intern
viru
dcspecif
nonintegrin
dcsign
also
known
carri
viru
activ
cell
b
cell
may
also
involv
earli
spread
infect
bind
viru
complement
receptor
also
known
viru
replic
rapidli
spread
throughout
bodi
lymphoid
tissu
particularli
gutassoci
lymphoid
tissu
galt
activ
memori
cell
present
high
number
approxim
cell
galt
infect
human
acut
infect
sivinfect
macaqu
uninfect
cell
site
becom
activ
die
apoptosi
result
releas
apoptot
microparticl
suppress
immun
function
therefor
cell
galt
deplet
first
week
infect
replic
galt
lymphoid
tissu
plasma
viraemia
increas
exponenti
reach
peak
usual
million
rna
copi
per
ml
blood
day
siv
infect
macaqu
day
infect
human
fig
cell
number
low
time
peak
viraemia
later
return
near
normal
level
blood
galt
although
b
cell
deplet
earli
infect
b
cell
respons
impair
owe
destruct
cell
type
import
develop
germin
centr
germin
centr
gut
lost
within
first
day
infect
attempt
make
vaccin
fail
three
vaccin
approach
test
clinic
trial
efficaci
aidsvax
glycoprotein
gp
vaccin
stimul
product
nonneutr
antibodi
viru
envelop
protein
fail
protect
vaccin
individu
infect
step
vaccin
compris
three
recombin
attenu
adenoviru
serotyp
virus
express
gag
pol
nef
stimul
cell
respons
viral
protein
show
protect
effect
similar
viru
vectorbas
vaccin
shown
stimul
simian
immunodefici
viru
siv
specif
cell
respons
rhesu
macaqu
adenoviru
serotyp
vector
express
gag
protect
challeng
chimer
sivhiv
viru
protect
challeng
natur
ref
recent
data
show
recombin
vaccin
stimul
much
broader
stronger
cell
respons
partial
protect
viru
challeng
result
attenu
infect
low
viru
load
prolong
surviv
rhesu
macaqu
third
efficaci
trial
thailand
use
canari
pox
viral
vector
express
gag
pol
prime
immun
respons
follow
aidsvax
vaccin
boost
immun
respons
report
recent
show
first
time
small
protect
effect
fewer
vaccin
recipi
becom
infect
control
result
statist
signific
one
three
analys
made
volunt
cohort
low
risk
annual
incid
infect
may
relev
may
easier
protect
peopl
high
risk
clear
whether
protect
mediat
antibodi
cell
innat
cell
combin
three
becom
infect
reduc
viru
level
usual
seen
protect
mediat
cell
siv
model
gener
consensu
field
futur
vaccin
approach
less
empir
deeper
understand
earliest
immun
respons
siv
infect
need
also
import
understand
broadspecif
neutral
antibodi
routin
induc
determin
way
safe
induc
identifi
immun
respons
lead
better
outcom
rare
individu
known
elit
control
success
control
infect
decad
without
need
antiretrovir
drug
therapi
highli
special
dynam
microenviron
locat
peripher
lymphoid
tissu
exampl
spleen
lymph
node
main
site
b
cell
matur
lead
gener
memori
b
cell
plasma
cell
produc
highaffin
antibodi
reveal
first
week
follow
infect
divid
clinic
stage
defin
stepwis
gain
posit
detect
antigen
antibodi
diagnost
assay
bracket
time
infect
first
detect
viral
rna
plasma
refer
eclips
phase
plasma
viru
level
increas
exponenti
peak
day
infect
follow
slower
decreas
plasma
viral
rna
level
patient
categor
fiebig
stage
ivi
base
sequenti
gain
posit
clinic
diagnost
assay
viral
rna
measur
pcr
viral
antigen
measur
enzymelink
immunosorb
assay
elisa
antibodi
detect
elisa
antibodi
detect
western
blot
patient
progress
acut
infect
earli
chronic
stage
infect
end
fiebig
stage
v
approxim
day
follow
infect
plasma
viral
load
begin
plateau
b
fundament
event
acut
infect
follow
infect
viru
first
replic
local
mucosa
transport
drain
lymph
node
amplif
occur
initi
phase
infect
system
viral
dissemin
begin
constitut
eclips
phase
time
viru
first
detect
blood
refer
exponenti
increas
plasma
viraemia
peak
day
infect
time
signific
deplet
mucos
cell
alreadi
occur
around
time
peak
viraemia
patient
may
becom
symptomat
reservoir
latent
viru
establish
cell
slower
rate
decay
cell
window
opportun
transmiss
peak
viraemia
prior
massiv
cell
destruct
establish
viral
reservoir
narrow
crucial
period
vaccin
must
control
viral
replic
prevent
extens
cell
deplet
curb
gener
immun
activ
part
modifi
permiss
ref
nation
academi
scienc
usa
part
b
modifi
ref
type
cell
character
express
forkhead
box
high
level
reg
cell
suppress
mani
type
immun
respons
establish
viral
set
point
point
peak
viraemia
immun
respons
affect
amino
acid
sequenc
viru
despit
extens
activ
innat
immun
cell
see
thereaft
viral
load
decreas
week
reach
stabl
level
known
viral
set
point
fig
viru
diversif
occur
decreas
viral
load
multipl
escap
mutant
select
pressur
adapt
immun
respons
first
detect
peak
viraemia
absenc
antiretrovir
drug
therapi
art
set
point
maintain
balanc
viru
turnov
immun
respons
death
rate
infect
cell
calcul
decay
curv
viraemia
art
initi
infect
memori
cell
halflif
less
day
howev
cell
popul
slower
rate
decay
cell
popul
cell
maintain
latent
pool
ref
cell
probabl
latent
infect
within
day
transmiss
unlik
remov
natur
vaccinestimul
immun
respons
given
elimin
art
cell
strike
featur
acut
infect
human
siv
infect
rhesu
macaqu
persist
vari
degre
chronic
infect
dysregul
immun
cell
limit
cell
infect
specif
ref
chronic
immun
activ
observ
natur
sivinfect
sooti
mangabey
infect
rare
progress
aid
despit
high
level
viru
replic
acut
cell
deplet
suggest
role
immun
activ
aid
develop
inde
posit
correl
marker
cell
activ
hiv
diseas
progress
immun
activ
associ
earli
extens
apoptosi
b
cell
lead
releas
apoptot
microparticl
blood
fig
increas
express
tumour
necrosi
factor
tnf
relat
apoptosisinduc
ligand
trail
also
known
fa
ligand
also
known
kill
bystand
cell
immunosuppress
caus
hivassoci
immun
activ
establish
earli
infect
clearli
defin
multipl
relat
event
review
ref
probabl
contribut
activ
includ
direct
viral
infect
immun
cell
proinflammatori
cytokin
product
innat
cell
drive
direct
bystand
activ
immun
cell
transloc
microbi
product
blood
damag
intestin
epithelium
loss
viral
infect
regulatori
reg
cell
chronic
mycobacteri
viral
coinfect
contrast
pathogen
infect
select
human
millennia
new
pathogen
human
therefor
influenc
host
genet
immun
respons
infect
may
evid
dramat
find
tnf
day
follow
transmiss
approach
involv
rapidli
scan
singl
nucleotid
polymorph
marker
across
complet
genom
mani
individu
find
genet
variat
associ
particular
diseas
snp
singl
nucleotid
variat
genom
dna
sequenc
one
four
nucleotid
substitut
anoth
snp
frequent
type
polymorph
genom
use
map
gene
connect
linkag
disequilibrium
amino
acid
sequenc
posit
domain
hla
class
heavi
chain
four
motif
sequenc
differ
posit
asn
asp
ser
ile
thr
motif
involv
recognit
certain
hla
allel
killer
immunoglobulinlik
receptor
regard
homozygos
base
pair
delet
abrog
express
protect
almost
complet
infect
furthermor
hla
allel
hlab
hlab
hlab
associ
good
control
viru
slower
progress
aid
partli
epitop
recogn
cell
individu
focus
conserv
region
viral
gag
protein
see
genomewid
associ
studi
found
strong
protect
influenc
singl
nucleotid
polymorph
snp
locat
kilobas
upstream
hlac
locu
confirm
associ
low
viral
set
point
hlaclink
snp
may
associ
lowlevel
express
hlac
might
turn
affect
cell
natur
killer
nk
cell
function
infect
contrast
subtyp
associ
rapid
diseas
progress
especi
homozyg
although
mechan
understood
shown
express
killer
immunoglobulinlik
receptor
deliv
activ
inhibitori
signal
nk
cell
respect
delay
progress
aid
individu
hla
class
allotyp
contain
variant
motif
thought
ligand
receptor
expans
nk
cell
express
andor
acut
infect
observ
hlab
motif
present
support
vitro
data
demonstr
nk
cell
express
control
replic
effici
hlab
target
cell
possibl
mediat
specif
recognit
hivinfect
cell
nk
cell
although
exact
natur
ligand
elus
observ
probabl
reflect
influenc
interact
andor
hlab
develop
andor
function
nk
cell
possibl
cell
may
help
control
viral
set
point
earli
innat
immun
respons
acutephas
protein
cytokin
insight
earliest
system
immun
respons
infect
gain
studi
plasma
donor
acquir
infect
frequent
sampl
taken
infect
peak
viraemia
seroconvers
sampl
differ
donor
align
rel
time
viral
rna
first
detect
copi
per
ml
first
detect
innat
immun
respons
occur
sometim
increas
level
acutephas
protein
serum
amyloid
h
kramer
b
kessler
person
commun
wave
acutephas
protein
product
coincid
cytokin
respons
describ
rapid
increas
plasma
viraemia
product
acutephas
protein
trigger
proinflammatori
cytokin
also
extrins
factor
lipopolysaccharid
lp
lp
detect
plasma
chronic
infect
siv
may
deriv
commens
bacteria
transloc
gut
lumen
follow
deplet
intestin
helper
cell
immunostain
galt
biopsi
collect
acut
infect
patient
show
higher
level
proinflammatori
cytokin
healthi
tissu
viraemia
increas
level
cytokin
chemokin
plasma
fig
level
type
interferon
ifn
cxcchemokin
ligand
increas
rapidli
transient
tnf
also
increas
rapidli
sustain
high
level
wherea
increas
slightli
delay
fig
cytokin
antivir
activ
exampl
type
ifn
inhibit
hiv
replic
sever
combin
immunodefici
mice
reconstitut
human
lymphocyt
also
type
ifn
enhanc
innat
adapt
immun
respons
howev
intens
cytokin
respons
acut
hiv
infect
may
also
promot
viral
replic
mediat
immunopatholog
discuss
cellular
sourc
acutephas
cytokin
chemokin
earli
infect
definit
identifi
probabl
includ
infect
cell
activ
dc
monocyt
macro
phage
nk
cell
nkt
cell
subsequ
hivspecif
cell
cytokin
storm
observ
earli
infect
much
greater
observ
acut
hepat
b
hepat
c
viru
infect
indic
system
cytokin
respons
magnitud
prerequisit
viral
clearanc
intens
cytokin
respons
acut
hiv
infect
may
instead
fuel
viral
replic
mediat
immunopatholog
discuss
highlevel
system
cytokin
respons
acut
infect
avian
influenza
viru
sever
acut
respiratori
syndromeassoci
coronaviru
likewis
associ
immunopatholog
consequ
group
protein
includ
creactiv
protein
serum
amyloid
complement
compon
fibrinogen
secret
blood
increas
decreas
quantiti
hepatocyt
respons
trauma
inflamm
diseas
protein
inhibitor
mediat
inflammatori
process
subset
helper
cell
produc
thought
import
antibacteri
antifung
immun
may
also
role
autoimmun
diseas
gener
involv
well
transcript
factor
retino
acidrel
orphan
signal
transduc
activ
transcript
envelop
protein
hiv
initi
produc
precursor
glycoprotein
kda
cleav
gener
three
molecul
three
molecul
thought
combin
trimer
form
envelop
spike
stage
infect
defin
seri
laboratori
test
measur
emerg
antibodi
viral
rna
viral
antigen
dc
markedli
reduc
number
acut
infect
n
bhardwaj
pb
unpublish
observ
rapid
declin
circul
dc
particularli
plasmacytoid
dc
pdc
may
due
activationinduc
cell
death
migrat
activ
dc
lymph
node
increas
dc
number
observ
vitro
pdc
becom
activ
bind
viral
envelop
protein
express
pdc
follow
virion
endocytosi
trigger
tolllik
receptor
viral
rna
howev
hivexpos
convent
dc
becom
fulli
activ
show
defect
product
consist
low
level
observ
acut
hiv
infect
addit
hivexpos
pdc
produc
enhanc
adapt
immun
respons
howev
hivexpos
pdc
also
produc
indoleamin
ido
induc
differenti
cell
reg
cell
might
suppress
hivspecif
immun
respons
convent
dc
prime
virusspecif
cell
respons
follow
vitro
exposur
hiv
prior
peak
viraemia
blood
nk
cell
prolifer
show
enhanc
activ
test
ex
vivo
nk
cell
popul
express
andor
expand
acut
infect
individu
also
express
hlab
nk
nkt
cell
control
hiv
replic
cytolysi
viral
infect
cell
product
antivir
cytokin
chemokin
addit
interact
dc
therebi
influenc
cell
respons
evolv
strategi
reduc
express
ligand
nk
cell
receptor
infect
cell
find
clear
role
molecul
determin
viral
set
point
support
involv
nk
cell
control
howev
time
nk
cell
antivir
effect
remain
uncertain
nk
cell
contribut
select
viru
escap
mutant
peak
viraemia
although
possibl
prove
account
unexplain
mutat
appear
togeth
select
earli
cell
respons
viraemia
decreas
reach
set
point
altern
antivir
effect
nk
andor
nkt
cell
might
greater
influenc
later
time
point
protect
potenti
innat
immun
respons
har
vaccin
nk
cell
share
charact
istic
memori
cell
initi
activ
may
possibl
prime
antivir
activ
vaccin
howev
activ
innat
immun
attempt
caution
innat
immun
respons
also
harm
exampl
induct
mucos
inflammatori
respons
microbicid
led
increas
acquisit
infect
review
ref
furthermor
discuss
earlier
activ
dc
transmit
viru
cell
eclips
phase
infect
chemokin
produc
pdc
recruit
suscept
cell
foci
infect
immun
activ
induc
innat
immun
cell
result
product
proinflammatori
cytokin
chemokin
promot
replic
type
ifn
tnf
also
proapoptot
effect
therebi
contribut
loss
activ
dc
bystand
destruct
cell
b
cell
oppos
effect
innat
immun
activ
highlight
studi
administ
treat
acut
siv
infect
rhesu
macaqu
nk
cell
sivspecif
cell
number
increas
result
fewer
sivinfect
cell
lymph
node
activ
prolifer
cell
enhanc
higher
viral
load
establish
therefor
vaccineinduc
activ
innat
immun
respons
thoroughli
test
macaqu
siv
model
use
caution
human
cell
respons
earli
infect
first
antibodi
detect
fiebig
stage
ii
similar
siv
infect
macaqu
first
cell
respons
infect
aris
viraemia
approach
peak
cell
respons
peak
week
later
viraemia
declin
homogen
founder
viru
time
peak
viraemia
indic
immunedriven
select
escap
mutant
viraemia
increas
follow
peak
cell
respons
viru
sequenc
start
chang
dramat
rapid
select
mutat
occur
discret
site
viru
genom
viraemia
declin
viral
set
point
fig
detail
analysi
four
patient
earli
stage
infect
indic
amino
acid
chang
viru
select
cell
recogn
epitop
express
founder
viru
escap
mutant
viru
mutat
viral
envelop
protein
select
neutral
antibodi
appear
later
week
minor
viru
escap
mutant
associ
demonstr
cell
respons
mutat
probabl
revers
sequenc
transmit
viru
select
cell
patient
sexual
partner
other
may
select
antibodydepend
cellmedi
viru
inhibit
nk
cell
notabl
celland
antibodymedi
select
viral
escap
mutant
rare
involv
singl
amino
acid
chang
epitop
mutant
involv
multipl
chang
variou
mutant
test
fittest
select
first
cellselect
mutat
could
replac
origin
sequenc
founder
viru
within
day
follow
sequenti
select
escap
mutat
differ
epitop
pattern
continu
throughout
cours
hiv
infect
chang
sequenc
could
involv
amino
acid
upstream
cell
epitop
probabl
import
antigen
process
natur
review
immunolog
earliest
cell
respons
often
specif
env
nef
respons
viral
protein
includ
conserv
gag
pol
protein
tend
aris
later
wave
cell
respons
may
import
maintain
viral
load
set
point
control
earli
viraemia
often
first
cell
respons
declin
rapidli
escap
mutat
select
may
declin
exhaust
loss
cell
viru
mutat
impli
complet
loss
epitop
tendenc
viru
revert
origin
sequenc
loss
fit
find
escap
mutant
appear
rapidli
rais
question
regard
effect
earli
cell
respons
mathemat
model
provid
answer
rapid
loss
founder
viru
sequenc
replac
escap
mutant
virus
impli
complet
cellmedi
inhibit
viru
product
infect
cell
rate
loss
founder
viru
sequenc
fraction
cell
kill
per
day
calcul
earliest
cell
respons
virusinfect
cell
lifespan
day
vivo
mean
infect
cell
must
kill
prematur
singl
cell
respons
must
reduc
viru
product
therefor
cell
curb
viraemia
acut
infect
howev
select
escap
mutant
would
minim
benefici
effect
mutant
fit
founder
viru
earliest
respons
immedi
succeed
new
cell
respons
new
mutat
epitop
turn
may
select
escap
mutant
fig
ultim
respond
cell
target
epitop
highli
conserv
escap
occur
cost
fit
viru
immunodomin
respons
highli
conserv
epitop
like
result
lower
level
viraemia
set
point
viru
undergon
escap
mutat
transmit
set
point
also
lower
new
host
level
set
point
viraemia
therefor
influenc
natur
transmit
viru
specif
earli
cell
respons
immunodomin
cell
respons
conserv
immunodomin
viru
epitop
like
result
lower
viral
set
point
cell
also
import
mainten
viral
set
point
mani
report
viru
escap
mutat
around
time
set
point
reach
use
mathemat
model
describ
earlier
cell
thought
make
small
contribut
kill
virusinfect
cell
per
day
infectedcel
death
chronic
infect
rest
due
viru
cytopath
infectedcel
activ
howev
may
underestim
cell
contribut
fit
cost
escap
mutat
viru
mutant
virus
grow
slowli
founder
viru
epitop
recogn
cell
later
stage
infect
highli
conserv
viru
must
undergo
compens
mutat
site
escap
occur
slow
outgrowth
mutant
virus
calcul
confound
difficulti
simultan
viru
escap
one
cell
respons
contrast
earliest
stage
infect
rang
epitop
recogn
cell
respons
narrow
later
respons
broad
often
direct
epitop
respons
conserv
epitop
probabl
import
longterm
control
viral
load
patient
hlab
hlab
hlab
well
clinic
cell
recogn
lessvari
region
viru
particularli
gag
quasispeci
patient
escap
slowli
longterm
infect
escap
mutant
incur
prove
fit
cost
viru
time
take
first
cell
respons
becom
target
conserv
epitop
might
import
determin
longterm
control
viral
infect
clear
featur
determin
cell
epitop
becom
immunodomin
clear
hla
type
import
precursor
frequenc
naiv
cell
specif
hiv
protein
also
like
factor
probabl
influenc
genet
histori
previou
crossreact
antigen
exposur
vaccin
could
influenc
cell
respons
infect
significantli
deplet
memori
cell
cell
particularli
suscept
infect
cell
respons
hiv
protein
alway
difficult
show
dispar
measur
cell
respons
antigen
observ
cytokin
product
versu
prolifer
nevertheless
sever
epitop
cell
identifi
particularli
gag
expans
hivspecif
cell
respons
occur
acut
infect
respons
declin
rapidli
although
earli
administr
art
control
viraemia
prevent
kill
cell
rescu
strong
cell
respons
howev
even
probabl
suboptim
help
weaken
cell
repertoir
first
cell
respons
strong
although
progress
longterm
memori
cell
could
impair
rapid
declin
cell
respons
observ
founder
epitop
elimin
viru
plasma
owe
escap
mutat
consist
impair
longterm
cell
memori
observ
model
mice
deplet
cell
implic
vaccin
develop
find
describ
suggest
role
cell
earliest
immun
control
acut
infect
cell
develop
abnorm
becom
dysfunct
infect
progress
review
ref
earli
cell
respons
seem
function
normal
g
ferrari
person
commun
although
factor
contribut
low
viru
set
point
good
longterm
prognosi
without
art
known
clear
cell
import
compon
vaccin
complet
prevent
infect
benefit
stimul
appropri
cell
respons
shown
recent
macaqu
siv
model
effect
vaccin
would
need
stimul
cell
respons
multipl
epitop
especi
highli
conserv
would
also
favour
stimul
broad
cell
respons
recogn
common
variant
founder
viru
epitop
sequenc
would
limit
escap
option
antibodi
neutral
autolog
viru
develop
slowli
aris
week
longer
transmiss
antibodi
show
degre
neutral
heterolog
viru
eventu
aris
patient
year
infect
determin
specif
kinet
antibodi
product
transmiss
understand
broadli
reactiv
neutral
antibodi
made
acut
hiv
infect
import
studi
earliest
b
cell
respons
transmit
viru
envspecif
antibodi
respons
autolog
consensu
env
epitop
determin
plasma
donor
cohort
describ
earlier
innat
immun
first
detect
b
cell
respons
found
occur
day
form
immun
complex
wherea
first
free
antibodi
plasma
specif
env
glycoprotein
gp
appear
day
contrast
appear
env
antibodi
delay
addit
day
product
nonneutr
envspecif
antibodi
fig
tabl
first
iga
respons
mucos
secret
detect
within
first
week
also
recogn
acut
hiv
infect
n
l
yate
gdt
unpublish
observ
studi
appli
mathemat
model
earli
viral
dynam
indic
initi
igg
igm
respons
significantli
affect
earli
dynam
plasma
viral
load
acut
antibodi
select
escap
mutat
indic
earli
aris
antibodi
ineffect
similar
analys
effect
initi
immun
complex
iga
respons
viral
dynam
need
understand
interplay
initi
host
antibodi
respons
viru
replic
known
initi
antibodi
respons
env
nonneutr
may
relat
immunodomin
denatur
nonfunct
env
form
first
antibodi
induc
escap
mutant
autologousvirusneutr
antibodi
develop
week
transmiss
tabl
fc
receptor
somaticrecombin
process
class
immunoglobulin
switch
igm
igg
iga
ige
fcr
mediat
complementassoci
antihiv
effector
function
also
report
primari
infect
howev
studi
requir
defin
role
capac
select
escap
mutat
rang
epitop
bound
first
specif
autolog
viru
neutral
antibodi
clade
c
infect
narrow
epitop
often
restrict
certain
viru
isol
similar
infect
clade
b
initi
autologousvirusneutr
antibodi
induc
clade
c
infect
induc
similar
kinet
usual
specif
initi
transmit
env
variant
although
autologousvirusneutr
antibodi
respons
control
viru
quasispeci
present
antibodi
appear
infect
clade
b
c
virus
narrow
respons
allow
rapid
viral
escap
k
bar
g
shaw
person
commun
broadspecif
neutral
antibodi
conserv
env
region
rare
interestingli
antibodi
specif
conserv
region
env
carbohydr
epitop
recogn
uniqu
broadspecif
neutral
monoclon
antibodi
ref
site
recogn
monoclon
antibodi
ref
membraneproxim
region
recogn
monoclon
antibodi
rare
gener
infect
occur
develop
month
infect
observ
indic
genet
factor
matur
antibodi
respons
necessari
gener
rare
late
broadspecif
neutral
antibodi
respons
affin
matur
somat
hypermut
may
crucial
gener
neutral
antibodi
may
delay
impair
cell
help
monoclon
antibodi
long
hydrophob
complementaritydetermin
region
sequenc
show
polyreact
autolog
molecul
suggest
b
cell
regulatori
mechan
self
toler
may
control
product
acut
infect
profoundli
affect
blood
tissu
b
cell
induc
earli
class
switch
polyclon
b
cell
associ
mark
increas
number
blood
tissu
memori
b
cell
plasma
cell
well
decreas
number
naiv
b
cell
mucos
b
cell
antibodydepend
cellmedi
cytotox
adcc
cytotox
mechan
antibodyco
target
cell
directli
kill
leukocyt
express
fcr
nk
cell
macrophag
neutrophil
induct
microenviron
peyer
patch
hiv
siv
replic
high
level
acut
infect
ref
siv
induc
lysi
follicular
b
cell
massiv
b
cell
apoptosi
loss
germin
centr
within
first
day
infect
earli
loss
germin
centr
may
result
defect
abil
rapidli
gener
highaffin
antibodi
lead
delay
induct
autologousvirusneutr
antibodi
implic
vaccin
design
find
gener
potenti
protect
antibodi
delay
initi
control
viraemia
week
transmiss
focus
epitop
impli
import
develop
vaccin
prime
earli
broad
antibodi
respons
target
multipl
neutral
epitop
effect
control
earli
viral
expans
natur
process
littl
late
earli
perturb
b
cell
viru
similarli
indic
need
vaccin
either
high
level
durabl
protect
antibodi
respons
prime
order
induc
rapid
secondari
respons
rariti
broadspecif
neutral
antibodi
respons
conserv
epitop
env
emphas
need
search
find
small
b
cell
subset
make
broadspecif
neutral
antibodi
immunogen
adjuv
need
target
specif
b
cell
outlook
clear
pictur
earliest
immun
respons
fig
major
implic
prevent
gener
vaccin
design
transmiss
probabl
day
window
eclips
phase
virusinfect
cell
could
erad
viru
spread
wide
integr
gener
longlast
noneradic
reservoir
latent
viru
true
steril
immun
attain
viru
prevent
infect
host
cell
could
achiev
broadspecif
neutral
antibodi
alreadi
present
plasma
mucos
site
viru
transmiss
support
hypothesi
shown
local
applic
intraven
inject
neutral
monoclon
antibodi
siv
macaqu
protect
subsequ
challeng
viru
neutral
antibodi
gener
suffici
quantiti
affin
breadth
immun
mechan
could
abort
infect
attack
founder
viru
andor
first
infect
cell
cellmedi
kill
antibodymedi
mechan
depend
fcr
includ
antibodydepend
cellmedi
cytotox
adcc
nk
cellmedi
lysi
releas
potenti
prevent
earli
infect
howev
prevent
infect
effector
mechan
would
readi
prime
time
activ
expand
central
memori
cell
exampl
chronic
infect
establish
har
nk
cell
nkt
cell
might
effect
strategi
control
increas
viral
infect
cell
eclips
phase
increas
viraemia
earli
infect
although
may
hazard
induc
chronic
hyperactiv
cell
mean
inhibit
viru
infect
may
possibl
immun
subject
antigen
peptid
specif
expand
potenti
protect
nk
nkt
cell
subpopul
therebi
alter
cell
repertoir
contain
higher
proport
protect
nk
cell
modest
protect
offer
vaccin
use
recent
clinic
trial
carri
thailand
volunt
low
risk
infect
may
exampl
weak
immun
respons
combin
rais
threshold
infect
rare
event
infect
start
spread
enhanc
natur
contain
process
might
immunolog
option
benefit
infect
individu
cell
respons
clearli
effect
reduc
peak
viraemia
acut
infect
could
enhanc
vaccin
increas
breadth
epitop
recognit
rather
mediat
sequenti
respons
singl
epitop
would
simultan
multiepitopespecif
cell
respons
viru
focus
respons
conserv
epitop
escap
incur
fit
cost
viru
would
desir
strategi
enhanc
preserv
cell
help
would
also
benefit
support
cell
howev
import
recogn
cell
highli
sensit
singl
amino
acid
variat
epitop
peptid
even
minor
mismatch
vaccineencod
epitop
viral
epitop
could
seriou
problem
could
diminish
effect
vaccinestimul
cell
respons
vaccin
induc
greater
breadth
earli
b
cell
respons
occur
natur
acut
infect
use
combin
protect
epitop
prevent
vaccin
may
control
earli
dissemin
result
lower
viral
set
point
better
longterm
immun
control
preliminari
unpublish
result
experiment
vaccin
includ
multipl
common
variant
protein
gag
mosaic
vaccin
shown
enhanc
breadth
magnitud
cell
respons
anim
studi
approach
novel
strategi
expand
breadth
induc
envspecif
b
cell
respons
also
central
improv
prospect
vaccin
success
thought
good
news
transmiss
result
product
infect
mediat
one
virion
indic
vulner
viru
immun
attack
eclips
phase
suggest
welldesign
vaccin
strategi
might
chanc
achiev
good
perfect
control
around
time
acut
peak
viraemia
prevent
onset
damag
chronic
immun
activ
damag
gener
immun
cell
environ
howev
vaccin
strategi
must
develop
potenti
clearli
qualit
quantit
insuffici
immun
respons
first
week
infect
hope
innat
adapt
arm
immun
system
har
develop
vaccin
ensur
adequ
immun
protect
place
transmiss
enabl
earlier
broader
effect
secondari
respons
prevent
control
acut
infect
